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The search for the infectious agents responsible for cat-scratch disease, bacillary
angiomatosis, and related syndromes has a long and often circuitous history. Recog-
nition of the etiologic agents and a new understanding of the fundamental features
of the epidemiology and natural history of modern day Bartonella (formerly Rochali-
maea)-associated diseases culminate a multipartite story that combines clinical
medicine, traditional microbiology, and novel technological approaches to solve a
long-standing enigma.
The quest for the etiologic agent of cat-scratch
disease (CSD) has frequently been described as a
mystery (1,2). Indeed, the search has many qualities
of a mystery novel; the pursuit has spanned several
decades and recently taken several unexpected
turns. During this period of important discovery,
major microbial suspects have undergone name
changes, novel microbial culprits have been intro-
duced, new groups of affected patients have been
recognized, and yet significant questions remain to
be answered. Scientific and medical interest has
been high; approximately 900 publications have
dealt with CSD since the first good clinical descrip-
tion of the disease in 1950 (3).
Clinical Features of CSD
Throughout the life of this evolving mystery, the
clinical descriptions of “classical” CSD have re-
mained remarkably consistent (Dalton MJ, et al.
Rochalimaea antibody; a new era in the diagnosis of
cat-scratch disease, submitted for publication; 4-6).
CSD is typically a benign and self-limited illness
lasting 6 to 12 weeks in the absence of antibiotic
therapy. Regional lymphadenopathy (axillary, head
and neck, inguinal) is the predominant clinical fea-
ture of CSD; affected nodes are often tender and
occasionally suppurate (4-7). Between 25% and 60%
of patients report a primary cutaneous inoculation
lesion (0.5- to 1-cm papule or pustule) at the site of
a cat scratch or bite (5,7). The skin lesions typically
develop 3 to 10 days after injury and precede the
onset of lymphadenopathy by 1 to 2 weeks. Low-
grade fever and malaise accompany lymphade-
nopathy in up to 50% of patients; headache, ano-
rexia, weight loss, nausea and vomiting, sore throat,
and splenomegaly may develop. In addition, short-
lived, non-specific maculopapular eruptions,
erythema nodosum, figurate erythemas, and throm-
bocytopenic purpura have been observed (8).
Unusual manifestations of CSD, which occur in
up to 14% of patients, include Perinaud’s oculoglan-
dular syndrome (6%), encephalopathy (2%), hepatic
granulomas (0.3%), osteomyelitis (0.3%), and pulmo-
nary disease (0.2%) (4,5,8). In general, these compli-
cations resolve without sequelae. Perinaud’s
oculoglandular syndrome is manifested by conjuncti-
val granuloma, periauricular lymphadenopathy, and
nonsuppurative conjunctivitis. Encephalopathy,
manifested as fever and coma that progress to con-
vulsions, may last for days to weeks; cerebrospinal
fluid is unremarkable. Optic neuritis with transient
blindness may also occur.
For many years, CSD has been clinically diag-
nosed when three of the following four criteria are
met in a patient: 1) history of traumatic cat contact;
2) positive skin-test response to CSD skin-test anti-
gen; 3) characteristic lymph node lesions; and 4)
negative laboratory investigation for unexplained
lymphadenopathy (8). Although biopsy confirmation
of CSD has been rarely required (especially in lieu
of a reliable serologic test—see below), a constant
pathologic hallmark of CSD-affected tissues has
been granuloma formation. With hematoxylin and
eosin stains, the primary inoculation lesion of CSD
reveals small areas of frank necrosis surrounded by
concentric layers of histiocytes, lymphocytes, and
nucleated giant cells (9). Affected lymph nodes are
characterized by necrotizing granulomas ringed by
lymphocytic infiltrates and  multinucleated giant
cells.
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During the past 44 years, a variety of microbial
agents, including herpes viruses and bacteria of the
genera Chlamydia and Pasteurella, have been sus-
pected as the causes of CSD (3). A major chapter of
the CSD saga unfolded with the 1988 announcement
by the Armed Forces Institute of Pathology that a
bacterial agent had been visualized within CSD-in-
volved lymph nodes by using the Warthin-Starry
silver stain (10), and a novel bacterial agent had
been isolated from a CSD patient’s lymph node (11).
By 1992, this agent was characterized fully, given
the name Afipia felis (Afipia being a latinized acro-
nym for the source of the original isolate, the Armed
Forces Institute of Pathology, and felis referring to
the presumed vertebrate vector of the human infec-
tion), and proclaimed the agent of CSD (12).
Although A. felis was declared the putative CSD
bacillus, evidence of convincing patient humoral or
cellular immune responses to laboratory cultured A.
felis antigen was not forthcoming. Despite numerous
attempts, other laboratories were unable to recover
additional isolates of A. felis from CSD patients. In
addition, although the majority of patients with CSD
reported exposure to a cat(s), no clear link between
cats and A. felis was demonstrated.
Enter New Syndromes
The story of CSD took a significantly divergent
path with the recognition that opportunistic infec-
tions were an important consideration for patients
infected with human immunodeficiency virus (HIV).
Bacillary angiomatosis (BA), a newly recognized dis-
ease characterized by cutaneous and subcutaneous
vascular lesions containing bacillary organisms
visualized by Warthin-Starry silver staining, was
described predominantly among HIV-infected pa-
tients; however, bacterial isolates were not made or
identified (13-15). Over the ensuing decade, the
clinical spectrum of BA was expanded to include
patients with single or multiple vascular lesions
affecting virtually every organ  system, including
lymph node, bone, brain, liver (peliosis hepatis), and
spleen (14-17). Independently, an unidentified gram-
negative pathogen was isolated predominantly from
HIV-infected patients with fever and bacteremia,
however, these patients lacked cutaneous or
parenchymal vascular lesions and were not recog-
nized as BA patients (18).
Because silver staining and electron microscopy
of both BA and CSD tissue sections revealed bacil-
lary organisms indistinguishable from one another,
several authors suggested that BA might represent
disseminated CSD in the immunocompromised host
(17,19-21). In addition, several anecdotal reports of
BA described a history of cat contact preceding the
onset of disease (22).
Ultimately, the relationships between possible
environmental exposures and BA or CSD were sys-
tematically investigated. The first case-control
study conducted among patients with BA found
traumatic contact with a cat (bite or scratch) to be
significantly associated with BA disease (22). BA
patients were also more likely than controls to have
a household kitten (a cat <1 year of age). A subsequent
case-control study of CSD patients found that these
patients were more likely than controls to have trau-
matic contact with a cat, to own at least one kitten, and
to have kittens with fleas (7).
Despite the similarities in histochemical staining
properties and epidemiology, serious reservations
remained concerning a possible link between the
causative agents of CSD and BA. The pathologic
features of classical CSD (granuloma) and BA (pro-
liferative vascular lesions without granuloma) were
distinctly different, and the two diseases seemed to
respond differently to antibiotic therapy. Although
antimicrobial therapy for BA and CSD have not been
systematically evaluated, the majority of BA pa-
tients evaluated responded quickly to single-agent
therapy with either erythromycin or doxycycline
(14,23), whereas the symptoms and signs of patients
with CSD failed to show consistent rapid resolution
following antibiotic therapy (5). In addition, clini-
cians’ first choices of antibiotics for treating BA and
CSD vary (5,6,14,23).
Enter Rochalimaea henselae
A breakthrough occurred when a novel approach
was used to identify possible prokaryotic ribosomal
DNA extracted from BA skin lesions. When prokary-
otic ribosomal gene DNA extracted from BA lesions
and amplified by polymerase chain reaction (PCR)
was compared with sequenced ribosomal genes from
other organisms, it become apparent that the agent
associated with BA in this study was related to, but
not necessarily identical to, the agent of trench fever,
Rochalimaea quintana (24).
At nearly the same time in Oklahoma, Rochali-
maea-like organisms were being isolated on blood
agar from bacteremic patients (18). Independently
in Houston, Texas, fastidious, slow-growing Rochali-
maea-like isolates were recovered on several occa-
sions from the blood of an HIV-infected patient with
relapsing fever of unknown origin; like the isolates
from the Oklahoma patients, the Houston isolate
was recovered from a patient in the absence of BA or
CSD lesions (25). The Houston isolate (Houston-1)
was identified as the prototype isolate of a novel
species of Rochalimaea by using traditional as well
as genotypic methods, including ribosomal RNA
gene analysis similar to that used to identify the
nucleic acid found in BA patients’ lesions (25). Al-
most simultaneously, the group from Oklahoma had
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ness data (26); most of their isolates also consisted
of the novel species, R. henselae. The new species
designation, first officially used to describe the
Houston-1 isolate, was coined in recognition of the
contribution of Diane Hensel, a microbiologist who
had isolated several of the initial organisms in Okla-
homa (18,25,26). Subsequently, Koehler et al. iso-
lated bacilli directly from cutaneous lesions of
persons with BA (27); surprisingly, either R. henselae
or  R. quintana was isolated from BA lesions from
different HIV-infected patients.
At this juncture, R. henselae infections had been
described predominantly among immunocom-
promised patients with either BA or fever with bac-
teremia. The availability of isolates made it possible
to develop a test for serologic evidence of Rochali-
maea infection and to refine PCR methods for iden-
tification of Rochalimaea organisms in tissues and
other samples. These methods, together with new
techniques for recovering Rochalimaea species iso-
lates, were crucial to obtaining a more detailed ac-
count not only of BA but also of CSD.
The Cat-scratch Connection: A Synthesis
A  Rochalimaea genus-specific, indirect fluores-
cence antibody (IFA) test using irradiated whole cell
antigen from the Houston-1 isolate of R. henselae
was developed by the Centers for Disease Control
and Prevention (CDC) to help identify risk factors
for  Rochalimaea-associated disease. Several blinded
serum samples from both HIV-infected BA patients
and HIV-infected controls residing in San Francisco
were sent to CDC for serologic testing. High-titered
antibodies were identified in serum samples from
several of the BA patients (28). Similar high-titered
antibodies were not detected for any of non-BA con-
trol patients with one exception; a serum sample
from an HIV-infected patient with CSD also demon-
strated strong serologic reactivity to R. henselae
antigen.
Shortly thereafter, single sera collected from pa-
tients with suspected CSD to look for A. felis anti-
bodies were evaluated with the new R. henselae
serologic test; 36 (88%) of 41 sera were positive (29).
None of the sera had significantly elevated titers to
A. felis antigen. The same set of sera were coded and
resubmitted along with sera taken from other well-
characterized bacterial and viral diseases and tested
again in a blinded manner. The IFA test accurately
identified sera of case-patients with suspected CSD.
In addition, 6 (6%) of 107 sera from ostensibly healthy
persons, obtained from a commercial vendor, showed
antibody by IFA testing (29). These serologic data were
the first laboratory evidence suggesting that R. hense-
lae was associated with CSD.
Data further substantiating the role of R. hense-
lae in the etiology of CSD soon followed. The newly
developed serologic test was used to help investigate
a possible cluster of CSD cases in Connecticut; 38
(84%) of 45 suspected CSD cases had elevated Ro-
chalimaea antibody titers, whereas 4 (3.6%) of 112
age-matched controls had detectable antibody titers
(7). In another investigation, serum samples ob-
tained from 600 prospectively evaluated patients
with well-characterized CSD (i.e., persons with his-
tory of cat scratch, papule at site of inoculation, and
enlarged regional lymph node) had a 95% correla-
tion with positive Rochalimaea serology.
In 1993, R. henselae was isolated directly from the
lymph nodes of two CSD patients and was identified
by genotypic means; both patients had strong sero-
logic responses to Rochalimaea antigen (30). Evi-
dence of R. henselae-specific nucleic acid sequences
were found in 21 (84%) of 25 CSD lymph node tissues
submitted to CDC for evaluation (31).
Additional supporting evidence for a Rochali-
maea as the cause of CSD came from archival
sources. Skin-test antigen, used rather extensively
in the past to help diagnose examples of CSD (4,8),
consisted of pasteurized exudate collected from sup-
purative CSD lymph nodes. Among a cohort of CSD
patients who were skin-test positive, 52 (93%) of 56
had positive IFA antibody titers to the defined Ro-
chalimaea reagents (32). Furthermore, various lots
of skin-test antigen were shown by PCR analysis to
contain  Rochalimaea nucleic acid sequences (33),
and R. henselae sequences in particular (34). No
A. felis DNA sequences could be detected by PCR.
These data strongly indicated that microbiologically
undefined skin-test reagents, which had been used
for many years for the diagnosis and clinical charac-
terization of CSD, were in fact R. henselae reagents.
Collectively, these data supported a Rochalimaea
species etiology for both CSD and BA. Despite nu-
merous attempts, recent efforts to implicate A. felis
as a cause of either of these two clinical entities have
repeatedly failed.
Felis domesticus: A Reservoir for
Rochalimaea henselae
In addition to epidemiologic data, serologic evi-
dence also implicated domestic cats with Rochali-
maea-associated disease. Rochalimaea-specific IFA
antibodies were demonstrated in 6 (46%) of 13 pet
cats not associated with human disease and among
39 (81%) of 48 cats living in households reporting
human CSD in Connecticut (7). Microbiologic evi-
dence for the domestic cat as a reservoir for R.
henselae soon followed. R. henselae was isolated over
a 3-week period from the blood of a single cat not
linked to human illness (35). Investigations by Koe-
hler et al. established the cat as a reservoir for
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as the cause of cutaneous BA in three or four patients
with the disease. R. henselae was isolated from the
blood of all seven asymptomatic pet cats with which
these four BA patients had prolonged contact. The
prevalence of infection among cats in the greater
San Francisco Bay region was also studied; 25 (41%)
of 61 pet or impounded cats had asymptomatic R.
henselae bacteremia (36). R. henselae was also de-
tected by both direct culture and PCR from several
cat fleas combed from these bacteremic cats (36).
The human body louse (Pediculus humanus) was
established as a vector for human-to-human trench
fever  R. quintana transmission during the First
World War (37). Likewise, B. bacilliformis, a closely
related organism (see below) found in the mountains
of South America, can be transmitted by another
arthropod, the Phlebotomus sand fly (38). The obser-
vation that related microbes are vectored between
humans by arthropods adds credence to the pro-
posed role of arthropod vectors of CSD. Despite sev-
eral suggestions that fleas or possibly ticks (7,36,39)
are associated with R. henselae disease, no experi-
mental data exist to clearly demonstrate that ar-
thropods act as direct vectors.
Changes in Nomenclature: Rochalimaea
becomes Bartonella
Genotypic evaluation of members of the genus
Rochalimaea has led to the conclusion that members
of the genus are closely related to Bartonella bacil-
liformis, the agent of Carrión disease, Oroya fever,
and verruga peruana (40). Because of historical
precedence, the genus designation Bartonella is now
applied to all species of the old genus Rochalimaea
and replaces the Rochalimaea designation (species
names remain unchanged).
Physicians and researchers need to exercise care
in using the term “bartonellosis.” This term has
classically been used to describe the frequently fatal
syndromes caused by B. bacilliformis. To date,
B. bacilliformis and its associated syndrome (bar-
tonellosis) have been identified exclusively in South
America (38,41).
Remaining Questions for Ongoing and
Future Research
Although B. henselae is now regarded as the etio-
logic agent of CSD, as well as a cause of BA, endo-
carditis (42), and fever with bacteremia, many
questions remain unanswered. For example, why
did it take so long to isolate and identify B. henselae?
Part of the answer probably stems from the require-
ments necessary for growth in vitro, including en-
riched, non-selective blood agar incubated over a
prolonged period in a CO2 atmosphere. Most hospi-
tal laboratories discard their bacteriological plates
before primary isolates of B. henselae would be ex-
pected to appear (9-40 days). Extreme sensitivity to
a wide variety of antibiotics, at least in vitro, sug-
gests that residual levels of antibiotics in patients’
blood or other tissues (such as lymph node biopsy)
might inhibit Bartonella growth during primary iso-
lation attempts in vitro. Selective medium has yet
to be developed. Novel genotypic methods were cru-
cial for identification of B. henselae; thus, isolates
may well have been made in the past but remained
unidentified.
As mentioned above, it has become apparent that
in addition to B. henselae, B. quintana can also be
another significant cause of BA disease, at least
among immunocompromised patients in San Fran-
cisco (27). Another focus of B. quintana infections
(“urban trench fever”) has been identified among
homeless alcoholics in Seattle (43,44). How common
are B. quintana infections; are they louseborne and
vectored strictly between humans, as was believed
during World War I (37)? B. quintana-associated
disease has no known link with an alternative ver-
tebrate vector (such as cats).
Bartonella elizabethae is known only from a sin-
gle isolate from a man surviving endocarditis follow-
ing aortic valve-replacement surgery (45). Is there
further public health significance to this organism?
What additional Bartonella species have yet to be
identified and what diseases may they cause?
Members of the genus Bartonella are exquisitely
sensitive to antibiotics in vitro (30,46). Why then do
CSD patients not respond as rapidly and consis-
tently to antibiotic therapy as BA patients do? One
hypothesis is that immunocompetent patients some-
how sequester infectious organisms beyond  the
reach of antibiotics, whereas immunocompromised
patients do not. An alternative hypothesis regarding
differential antibiotic responsiveness recognizes
that many of the signs of CSD are immune mediated;
antibiotics, even if effective in neutralizing or killing
bacteria, may not immediately alleviate long-dura-
tion immunologic tissue manifestations of antigen
stimulation. Conversely, in the absence of the immu-
nologic capability to react to bacterial infection by
forming granulomas, as in the case of severely im-
munocompromised persons with BA, antibiotics are
generally effective in alleviating the symptoms and
signs of infection. Does this suggest that possible
non-granulomatous manifestations of CSD (for ex-
ample, neuroretinitis and encephalopathy) should
respond well to the appropriate antibiotic therapy?
Although BA has been described in immunocom-
petent patients (15), the vast majority of BA patients
are immunocompromised (14). What are the factors
explaining why B. henselae and B. quintana induce
vascular proliferative lesions, such as BA and
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in severely immunocompromised patients?
What percentage of the relatively large numbers
of undiagnosed febrile disease among HIV-infected
persons is in fact due to Bartonella species infec-
tions? The answer to this important question may
help alleviate significant morbidity among HIV-in-
fected patients. The potential for selection for drug-
resistance during long-term antimicrobial therapy
deserves scrutiny.
Does the 4%-6% of IFA antibody-positive, ostensi-
bly healthy “control” study populations suggest a
relatively common undercurrent of undiagnosed,
subclinical  Bartonella-associated disease?
Is it possible to immunize cats and thereby inter-
rupt B. henselae transmission to humans? Prelimi-
nary data suggest that asymptomatic bacteremia in
cats can be successfully treated with antimicrobial
therapy (36). Once cleared of bacteremia, are these
cats routinely susceptible to reinfection?
Are the complications occasionally associated
with CSD and BA associated with different strains
of Bartonella species or are the variations in clinical
presentation strictly functions of dose, route of in-
oculation, and immune status?
And finally, in what role, if any, will A. felis reap-
pear as an agent of human disease? Is A. felis respon-
sible for the relatively small number of cases of
CSD-like lymphadenopathy that have no evidence of
antibody to B. henselae? Or is there another expla-
nation for the originally proposed association be-
tween  A. felis and CSD that has not yet come to light?
The new recognition of the importance of Bar-
tonella-associated diseases will continue to spawn a
host of unanswered related questions. Whereas
novel subplots will continue to unfold, the new puz-
zles are no longer totally shapeless, and answers to
questions of natural history and epidemiology, en-
hanced diagnosis and treatment, and methods for
disease intervention should now begin to unfold
rapidly.
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